New understandings of disease diagnostics and treatment have fueled predictions of a transition from “sick-care” to more integrative health care systems. Recent withdrawals of blockbuster drugs Vioxx and Tysabri due to safety concerns highlight the dangers of a “one size fits all” drug development model. Taking the opposite approach, personalized medicine seeks to create differentiated strategies for the prevention and care of disease through the use of ‘tailored’ medications. Drawing from the convergence of pharmacogenomics and proteomics, personalized medicine promises to make the drug development process faster, cheaper and more effective while also improving drug safety. However, this paradigm shift also poses important ethical challenges (such as the need to balance commercial and public health priorities) that will need to be carefully addressed. During our breakfast discussion panel, three Bay Area senior executives will share their insights on the meaning and the future of the personalized medicine revolution, to which they have directly contributed as important actors within each of their respective companies.
7:30 to 8:00 light breakfast & networking
8:00 to 8:45 10 min talks by each of the 3 panelists
- Dr. Bob Cohen, Senior Director, Business Development, Genentech
- Thane Kreiner, Vice President, Corporate Affairs for Affymetrix,Inc.
- Martin L. Verhoef, President of Ciphergen’s Biosystems Division and an Executive Vice President of Ciphergen Biosystems, Inc.
- Panel moderated by Dr. Heather Koshinsky, CEO, President and Co-founder, Investigen, Inc.
8:45 to 9:00 Q&A; session with the audience